나노입자 위탁제조 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the nanoparticle contract manufacturing market size is expected to increase from USD 5.30 billion in 2025 to USD 5.90 billion in 2026 and reach USD 10.10 billion by 2031, growing at a CAGR of 11.41% over 2026-2031.

This report is Segmented by Particle (Lipid Nanoparticles, Polymeric Nanoparticles, and More), Modality (mRNA, Small Molecules, and More), Service Type (Pre-Formulation Screening and More), Application (Oncology and More), Client Type (Pharmaceutical and Biotechnology Companies and More), Delivery Route (Oral and More), and Geography. Market Forecasts are Provided in Value (USD).

Global Nanoparticle Contract Manufacturing Market Trends and Insights

Expansion of mRNA/siRNA Pipelines Requiring LNP Capacity

Moderna disclosed in its 2025 10-K that eight of fifteen clinical programs rely on external lipid-nanoparticle formulation because in-house suites are reserved for COVID-19 boosters. Similar outsourcing by BioNTech and Arbutus shows a clear preference to deploy capital toward R&D rather than toward GMP bricks-and-mortar. New FDA guidance now requires ≥80% encapsulation efficiency and a polydispersity index ≤0.2, elevating the analytical bar and favoring CDMOs that already run AF4-MALS and cryo-TEM assays . With platformized ionizable lipids cutting formulation timelines in half, sponsors can progress multiple pipeline assets concurrently.

Oncology Nanomedicine Adoption Sustaining Complex Particle Demand

Oncology held 34.87% revenue in 2025 on the back of PEGylated liposomes and polymeric carriers that temper systemic toxicity. Merck KGaA logged a significant jump in CDMO requests for antibody-drug conjugate cargos encapsulated in nanoparticles, confirming clinician preference for targeted delivery . NCI studies show solid-lipid nanoparticles triple tumor accumulation for paclitaxel versus Cremophor formulations, underlining the clinical upside. Intratumoral injections of TLR agonists further show systemic immune activation without cytokine storms, broadening nanoparticle use cases.

Complex Nano-CMC Characterization and Comparability Risk

FDA's 2024 Complete Response Letter to Translate Bio cited inadequate lipid-oxidation profiling, forcing a nine-month refile and underscoring regulatory stakes. Less than 20 CDMOs worldwide run validated AF4-MALS assays, narrowing sponsor choice and slowing tech transfer . Cryo-EM costs USD 5,000-10,000 per sample, a heavy burden for seed-stage ventures. Switching vendors mid-program can shift particle size by 10-20 nm, triggering bridging studies that add 12-18 months.

Other drivers and restraints analyzed in the detailed report include:

1. Outsourcing Acceleration Tied to Capex and Analytics Barriers
2. Regulatory Clarity Around Nano-CMC Expectations
3. High Cost, Scale-Up Risk, and Batch-Failure Sensitivity

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Lipid nanoparticles secured 32.16% revenue in 2025 and remain the primary workhorse for RNA therapeutics across the Nanoparticle Contract Manufacturing Market. Polymeric systems will grow at an 11.98% CAGR because PLGA and chitosan carriers enable oral dosing and sustained release that lipids struggle to match. Liposomes retain a solid niche in small-molecule oncology, delivering extended half-life and reduced cardiotoxicity. Dendrimers stay in prototype status due to high synthesis cost. Other formats, such as nanostructured lipid carriers and solid lipid nanoparticles, serve dermatology and ophthalmology, while inorganic particles are largely confined to imaging studies.

Polymeric platforms capitalize on FDA-approved excipients, lowering toxicology hurdles and shortening IND review. Evonik's Eudragit nanoparticles improved oral insulin bioavailability fourfold in Phase I, demonstrating how polymer chemistry can solve first-pass metabolism challenges. Samsung Biologics now lists six Phase II polymeric programs for diabetes and IBD, giving credibility to the segment. CDMOs offering both lipid and polymer lines can arbitrage demand swings and reduce capacity downtime, a tactical edge as the Nanoparticle Contract Manufacturing Market diversifies.

Small-molecule cargos held 28.13% of 2025 revenue, powered by nanoparticle-solubilized oncology agents. mRNA projects, however, will post an 11.89% CAGR on the way to 2031, propelled by infectious-disease vaccines and emerging self-amplifying constructs that permit lower dosing. Gene-editing payloads such as CRISPR-Cas9 ribonucleoproteins require ultra-pure LNPs optimized for endosomal escape, pushing analytical demands higher. Peptide and protein therapies leverage pH-sensitive polymeric particles to prevent enzymatic degradation. Circular RNA, stable at room temperature for six months, offers new logistical advantages for the Nanoparticle Contract Manufacturing Market.

The modality mix now attracts a wider sponsor base. Moderna lists fifteen non-COVID mRNA programs spanning cardiology and oncology, each depending on external formulation suites. BioNTech's melanoma neoantigen data showed objective response when delivered via customized LNPs, underscoring efficacy upside and fortifying outsourcing pipelines.

Geography Analysis

North America dominated the Nanoparticle Contract Manufacturing Market with 39.16% revenue in 2025, supported by more than 30 GMP-certified lipid-nanoparticle suites across Boston, San Francisco, and the Research Triangle. FDA final guidance that now mandates cryo-TEM and AF4-MALS for all IND submissions further entrenches demand for advanced U.S. capacity. Canada subsidizes domestic outsourcing through NRC Montreal, while Mexico's Toluca cluster offers near-shore cost arbitrage for early-stage U.S. sponsors.

Asia-Pacific is forecast to record an 11.84% CAGR, the fastest regional climb, as China's NMPA cleared eight LNP products in 2024-2025 and Indian CDMOs invested USD 500 million in new mixing lines. Samsung Biologics' USD 300 million expansion cements South Korea as a regional anchor. Australia leverages integrated Phase I units to woo local biotech trials, while Japan's PMDA guidance convergence reduces export hurdles.

Europe sits between these poles, strong in specialized ionizable-lipid chemistry through players like Polymun Scientific and Evonik. EMA's reflection paper harmonizes CMC demands, but the UK's separate MHRA pathway offers a faster alternative for some sponsors. Spain's Rovi facility secured Moderna's European supply, and Swiss-based Lonza remains the go-to vendor for late-stage programs. Emerging demand in Middle East & Africa and South America is limited by cold-chain gaps, though Brazil's Fiocruz and South Africa's Biovac are investing in nanoparticle vaccine lines.

1. AGC Biologics
2. Ardena
3. Catalent Biologics
4. CordenPharma
5. Curia
6. Danaher
7. Evonik Health Care
8. Fortis Life Sciences
9. Laboratorios Farmaceuticos Rovi
10. Lonza Group
11. Merck
12. Nanoform Finland
13. PCI Pharma Services
14. Polymun Scientific
15. Recipharm
16. Rentschler Biopharma
17. Samsung Group
18. ST Pharm
19. Thermo Fisher Scientific
20. Vernal Biosciences
21. Wuxi Biologics

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expansion of mRNA/siRNA pipelines requiring LNP-enabled CDMO capacity
  • 4.2.2 Oncology nanomedicine adoption sustaining complex nanoparticle demand
  • 4.2.3 Outsourcing acceleration due to capex, GMP, and analytics barriers
  • 4.2.4 Regulatory clarity and evolving CMC expectations for nanomedicines
  • 4.2.5 Platformization of LNP/analytical toolkits reducing time-to-clinic
  • 4.2.6 saRNA/circRNA programs creating novel formulation demand
• 4.3 Market Restraints
  • 4.3.1 Complex, evolving nano-CMC characterization and comparability risk
  • 4.3.2 High cost, scale-up risk, and batch failure sensitivity
  • 4.3.3 Lipid IP/licensing constraints and freedom-to-operate hurdles
  • 4.3.4 Cold-chain and aseptic constraints for nano-DP/fill-finish
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Particle
  • 5.1.1 Lipid nanoparticles
  • 5.1.2 Nanostructured lipid carriers
  • 5.1.3 Dendrimers
  • 5.1.4 Liposomes
  • 5.1.5 Polymeric nanoparticles
  • 5.1.6 Nanoemulsions
  • 5.1.7 Solid lipid nanoparticles
  • 5.1.8 Polymeric micelles
  • 5.1.9 Inorganic nanoparticles
• 5.2 By Modality / Payload
  • 5.2.1 mRNA
  • 5.2.2 Small molecules
  • 5.2.3 Gene editing cargos
  • 5.2.4 siRNA / ASO
  • 5.2.5 Peptides
  • 5.2.6 Vaccines
  • 5.2.7 DNA
  • 5.2.8 Proteins
  • 5.2.9 Therapeutic vaccines
• 5.3 By Service Type
  • 5.3.1 Pre-formulation screening
  • 5.3.2 Analytical & characterization
  • 5.3.3 Aseptic fill-finish & lyophilization
  • 5.3.4 Formulation development
  • 5.3.5 GMP clinical manufacturing (DP)
  • 5.3.6 Tech transfer & comparability
  • 5.3.7 Process development & scale-up
  • 5.3.8 GMP commercial manufacturing (DP)
  • 5.3.9 Stability & method validation
• 5.4 By Application
  • 5.4.1 Oncology
  • 5.4.2 Infectious diseases
  • 5.4.3 Genetic & metabolic disorders
  • 5.4.4 Cardiovascular & metabolic
  • 5.4.5 CNS
  • 5.4.6 Ophthalmology
  • 5.4.7 Respiratory
  • 5.4.8 Immunology/Inflammation
• 5.5 By Client Type
  • 5.5.1 Pharmaceutical and Biotechnology Companies
  • 5.5.2 Academic and Research Institutes
  • 5.5.3 Contract Research Organizations
• 5.6 By Delivery Route
  • 5.6.1 Intravenous (IV)
  • 5.6.2 Intramuscular (IM)
  • 5.6.3 Subcutaneous (SC)
  • 5.6.4 Inhalation
  • 5.6.5 Intratumoral
  • 5.6.6 Intrathecal
  • 5.6.7 Ocular
  • 5.6.8 Oral
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 India
    • 5.7.3.3 Japan
    • 5.7.3.4 South Korea
    • 5.7.3.5 Australia
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 AGC Biologics
  • 6.3.2 Ardena
  • 6.3.3 Catalent Biologics
  • 6.3.4 CordenPharma
  • 6.3.5 Curia
  • 6.3.6 Danaher Corporation
  • 6.3.7 Evonik Health Care
  • 6.3.8 Fortis Life Sciences
  • 6.3.9 Laboratorios Farmaceuticos Rovi
  • 6.3.10 Lonza
  • 6.3.11 Merck KGaA
  • 6.3.12 Nanoform Finland
  • 6.3.13 PCI Pharma Services
  • 6.3.14 Polymun Scientific
  • 6.3.15 Recipharm
  • 6.3.16 Rentschler Biopharma
  • 6.3.17 Samsung Biologics
  • 6.3.18 ST Pharm
  • 6.3.19 Thermo Fisher Scientific
  • 6.3.20 Vernal Biosciences
  • 6.3.21 WuXi Biologics

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment